Abstract
Introduction: Mohs Micrographic Surgery (MMS) is globally acknowledged as the gold standard for treatment of recurrent, infiltrative and aggressive non-melanoma skin cancers (NMSC). It achieves maximal tissue preservation, less scarring and deformity. USA is one of the advanced countries where it is widely used and has been found to be cost effective. This paper aims to review the differences in policy and cost analysis in both regions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have